Optinose reports preliminary fourth quarter 2024 XHANCE revenue of $22.4 million, indicating sustained prescription growth. Full results expected in March. Optinose, a pharmaceutical company ...

(MENAFN- GlobeNewsWire - Nasdaq) Preliminary XHANCE prescription growth rate from third quarter to fourth quarter 2024 estimated to be approximately 20% YARDLEY, Pa., Jan. 15, 2025 (GLOBE NEWSWIRE ...

YARDLEY, Pa., Jan. 15, 2025 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced ...

YARDLEY, Pa., Jan. 15, 2025 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced ...

(RTTNews) - Optinose, Inc. (OPTN), a pharmaceutical company focused on ear, nose and throat or ENT and allergy, announced Wednesday preliminary XHANCE (fluticasone propionate) net product revenue ...

“Our preliminary unaudited fourth quarter net product revenue of $22.4 million is in line with our prior guidance and demonstrates a sustained growth in XHANCE prescriptions through the fourth ...

Try Now>> See the top Preliminary XHANCE prescription growth rate from third quarter to fourth quarter 2024 estimated to be approximately 20%YARDLEY, Pa., Jan. 15, 2025 (GLOBE NEWSWIRE ...

"Our preliminary unaudited fourth quarter net product revenue of $22.4 million is in line with our prior guidance and demonstrates a sustained growth in XHANCE prescriptions through the fourth ...